Developing a range of products for US, EU markets: Aurobindo Pharma

The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed, Aurobindo Pharma Managing Director N Govindarajan said in an analyst call.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ez61yT
via IFTTT